1. Home
  2. Media
  3. News
  4. Bioiberica to launch Atopivet, their first dermatology-related product

Bioiberica to launch Atopivet, their first dermatology-related product

6 May 2016
Companion Animal Health

Atopivet is a novel product for the treatment of canine atopic dermatitis 

Dermatologic conditions in dogs are one of the most common causes of visits to veterinarian clinics, and, according to some experts, the prevalence of conditions such as Canine Atopic Dermatitis affects 10 to 15 percent of the entire canine population. To face this problem, Bioiberica Veterinaria has just launched its first dermatologic product, resulting from their research in this field: Atopivet. 

The effects of atopic dermatitis vary, as it might affect the amount of lipids in the external layer of the skin or it might alter the relative concentration of these. It can also cause skin lesions and increase the loss of trans-epidermal water, which in turn causes an increase in the exposure to cutaneous skill allergens and skin dehydration.

The beneficial effects of Atopivet for the management of atopic dermatitis in dogs are explained by ingredients such as nucleotides and hyaluronic acid, which restore and repair the skin by reducing the loss of trans-epidermal water or dehydration. This effect combines with that of eicosapentaenoic acid (EPA), which helps to improve inflammation, and gamma-linolenic acid (GLA) which reinforces the barrier action of epidermal lipids. Finally, other ingredients such as zinc oxide and Vitamin E help repair skin cells’ metabolism and improve dermatitis symptoms.

Initially, Atopivet will be sold in boxes of 60 or 180 soft gelatin capsules. The first results of the scientific trials were well received by the veterinarians who participated in the AVEPA workgroups which were organized during the AVEPA veterinarian specialists’ congress, held this past April.